ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

NVCR NovoCure Ltd

16.41
0.28 (1.74%)
2024年5月11日 - 終了
15分遅延
名称 銘柄コード 市場 種別
NovoCure Ltd NVCR NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.28 1.74% 16.41 08:59:25
始値 安値 高値 終値 前日終値
16.22 16.02 16.60 16.47 16.13
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/0220:01BWNovocure Secures New $400 Million Multi-Tranche Non-Dilutive..
2024/5/0220:00BWNovocure Reports First Quarter 2024 Financial Results
2024/4/2423:45BWResults of Novocure’s METIS Phase 3 Clinical Trial for..
2024/4/0520:00BWNovocure Announces 20 Presentations On Tumor Treating..
2024/4/0120:00BWNovocure to Report First Quarter 2024 Financial Results
2024/3/2909:07BWMETIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
2024/3/2902:51BWKlinische Phase-3-Studie METIS erreicht primären Endpunkt..
2024/3/2902:50BWL’essai clinique de phase 3 METIS a atteint son critère..
2024/3/2720:00BWMETIS Phase 3 Clinical Trial Met Primary Endpoint,..
2024/3/1120:00BWINNOVATE-3 Late Breaking Abstract Selected as a Best Oral..
2024/3/0606:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0508:39EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0507:56EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0207:06EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0207:01EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0106:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0106:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0106:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0106:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0106:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2221:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
2024/2/2221:06EDGAR2Form 8-K - Current report
2024/2/2221:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/2/2221:00BWNovocure Reports Fourth Quarter and Full Year 2023 Financial..
2024/1/1901:10DJNNovocure Shares Rise 17% After FDA Accepts Pre-Market..
2024/1/1821:01EDGAR2Form 8-K - Current report
2024/1/1821:00BWNovocure Announces FDA Acceptance of the PMA Application for..
2024/1/1306:57EDGAR2Form 3 - Initial statement of beneficial ownership of..
2024/1/0921:00EDGAR2Form 8-K - Current report
2024/1/0921:00BWNovocure Announces Last Patient Enrolled in Phase 3 TRIDENT..
2024/1/0821:10EDGAR2Form 8-K - Current report
2024/1/0821:00BWNovocure Announces Preliminary Full Year and Fourth Quarter..
2024/1/0506:10EDGAR2Form 8-K - Current report
2024/1/0506:05BWNovocure Appoints Dr. Nicolas Leupin as Chief Medical..
2023/12/2721:00BWNovocure to Participate in 42nd Annual J.P. Morgan..
2023/11/2821:30EDGAR2Form 8-K - Current report
2023/11/2821:30BWNovocure Announces Portfolio Prioritization and Strategic..
2023/11/2121:00BWNovocure to Participate in 35th Annual Piper Sandler..
2023/11/1022:00BWNovocure Announces Presentations on Tumor Treating Fields..
2023/11/0906:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/0405:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/0305:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/2620:03EDGAR2Form 8-K - Current report
2023/10/2620:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/10/2620:00BWNovocure Reports Third Quarter 2023 Financial Results
2023/10/1607:05BWNovocure Announces Presence at European Society for Medical..
2023/10/1221:00BWNovocure and Stanford School of Medicine to Establish Tumor..
2023/10/0220:00BWNovocure to Report Third Quarter 2023 Financial Results
2023/9/3006:00BWNovocure Announces Presence at American Society for..
2023/9/0905:01BWNovocure Highlights Use of Tumor Treating Fields Therapy in..

最近閲覧した銘柄

Delayed Upgrade Clock